Phase III Clinical Trials for the Spectrum of Alzheimer’s Disease and Age-related Cognitive Decline (R01)
|Incentive Type:||Grant Program|
Health And Safety, Research
|Governing Body:||National Institutes of Health|
|What’s it worth?:||$25,000,000|
The Phase III Clinical Trials for the Spectrum of Alzheimer’s Disease and Age-related Cognitive Decline program funds Phase II clinical trials of promising pharmacological and non-pharmacological interventions in individuals with age-related cognitive decline and Alzheimer’s in all stages. Examples of prioritizes projects include but are not excluded to:
- Pharmacological interventions that target eradication or progression of deposition of disease neuropathology
- Repurposed drugs that have promise for Alzheimer’s treatment
- New cognitive training or engagement approaches
- Aerobic exercise
- Sleep enhancement
- Mindfulness-based stress reduction
- Nutritional supplementation or adoption of specific dietary programs
- Combinations of interventions
$25 million is available for allocation with no budget limits per project. Proposal are expected to cover the actual needs of the proposed project and may cover maximum of five years.
This program does not have any cost sharing requirements. Applications must be complete and received before the deadline.